Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CPNG

Coupang Inc

Apr 10 • 04:00PM ET

19.76

+0.10 0.51 %

Consumer Cyclical • Internet Retail • USA • NYSE

Peers: AMZN BABA JD SHOP EBAY PDD SE ETSY MELI W

| Held by: VXF IWP IWF IWR SCHG VONG ITOT SCHX VT IWB

Index	-	P/E	176.27	EPS (ttm)	0.11	Insider Own	27.17%	Shs Outstand	1.67B	Perf Week	4.27%
Market Cap	36.13B	Forward P/E	35.34	EPS next Y	0.56	Insider Trans	1.48%	Shs Float	1.33B	Perf Month	5.27%
Enterprise Value	34.35B	PEG	0.35	EPS next Q	-0.03	Inst Own	59.32%	Short Float	3.44%	Perf Quarter	-11.98%
Income	208.00M	P/S	1.05	EPS this Y	-42.66%	Inst Trans	-0.27%	Short Ratio	1.82	Perf Half Y	-38.54%
Sales	34.53B	P/B	7.79	EPS next Y	786.55%	ROA	1.21%	Short Interest	45.76M	Perf YTD	-16.24%
Book/sh	2.54	P/C	5.63	EPS next 5Y	100.35%	ROE	4.77%	52W High	34.08 -42.01%	Perf Year	-5.90%
Cash/sh	3.51	P/FCF	70.50	EPS past 3/5Y	- -	ROIC	2.68%	52W Low	16.74 18.04%	Perf 3Y	26.67%
Dividend Est.	-	EV/EBITDA	33.84	Sales past 3/5Y	18.83% 23.61%	Gross Margin	29.37%	Volatility	3.46% 3.97%	Perf 5Y	-56.90%
Dividend TTM	-	EV/Sales	0.99	EPS Y/Y TTM	34.31%	Oper. Margin	1.44%	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.79	Sales Y/Y TTM	14.09%	Profit Margin	0.60%	RSI (14)	55.99	Recom	1.58
Dividend Gr. 3/5Y	- -	Current Ratio	1.04	EPS Q/Q	-116.73%	SMA20	2.97%	Beta	1.24	Target Price	27.44
Payout	0.00%	Debt/Eq	1.00	Sales Q/Q	10.92%	SMA50	4.69%	Rel Volume	0.49	Prev Close	19.66
Employees	108000	LT Debt/Eq	0.68	Earnings	Feb 26 AMC	SMA200	-24.07%	Avg Volume	25.12M	Price	19.76
IPO	Mar 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-134.48% -2.48%	Trades		Volume	12,223,737	Change	0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Initiated	Bernstein	Underperform	$17
Jan-16-26	Upgrade	Deutsche Bank	Hold → Buy	$25
Jan-12-26	Downgrade	Nomura	Buy → Neutral	$22
Sep-18-25	Initiated	Arete	Buy	$40
Aug-06-25	Upgrade	Nomura	Neutral → Buy	$35
Aug-06-25	Downgrade	Deutsche Bank	Buy → Hold	$27
Feb-26-25	Upgrade	Deutsche Bank	Hold → Buy	$28.50
Oct-07-24	Upgrade	Bernstein	Underperform → Outperform	$30
Sep-04-24	Upgrade	CLSA	Hold → Outperform	$18 → $31
May-16-24	Upgrade	UBS	Neutral → Buy	$26
May-03-24	Resumed	BofA Securities	Buy	$30
Apr-15-24	Upgrade	Citigroup	Neutral → Buy	$19 → $26
Feb-29-24	Upgrade	Deutsche Bank	Hold → Buy	$18.50 → $21
Jan-16-24	Downgrade	Citigroup	Buy → Neutral	$20 → $17
Dec-20-23	Downgrade	UBS	Buy → Neutral	$26 → $18.50
Aug-09-23	Downgrade	Deutsche Bank	Buy → Hold	$20
Mar-02-23	Downgrade	BofA Securities	Buy → Neutral	$27 → $18
Mar-01-23	Upgrade	Deutsche Bank	Hold → Buy	$20
Feb-09-23	Initiated	Barclays	Overweight	$20
Dec-01-22	Initiated	New Street	Buy	$25

Show Previous Ratings

Apr-02-26 04:21PM	Brokers Suggest Investing in Coupang (CPNG): Read This Before Placing a Bet (Quartz)
Mar-18-26 11:17AM	Los Angeles Small Business Spreads Global Reach with Coupang (Business Wire)
Mar-17-26 08:36PM	Coupang NVIDIA Collaboration on AI Factory Is Powering the Future of E-Commerce Logistics (Business Wire)
Mar-12-26 10:51AM	DoorDash Stock: Is DASH Underperforming the Consumer Cyclical Sector? (Barchart)
Mar-10-26 01:45AM	Barclays Raises PT on Coupang, Inc. (CPNG) to $24 (Insider Monkey)
12:02PM	Loading…
Mar-08-26 12:02PM	Coupang (CPNG) Q4 2025 Earnings Impacted by Data Incident Involving 33M Accounts (Insider Monkey)
06:19AM	Morgan Stanley Maintains Overweight Rating on Coupang (CPNG) (Insider Monkey)
Mar-05-26 09:13AM	Should You Hold Coupang (CPNG)? (Insider Monkey)
Mar-04-26 07:30PM	E-commerce Giant Coupang Moves to Build Stablecoin Legal Team (BeInCrypto)
07:10AM	U.S. Tech Company Coupang Named a 2026 LexisNexis Top 100 Global Innovator (Business Wire)
Mar-03-26 09:30AM	Wall Street Bulls Look Optimistic About Coupang (CPNG): Should You Buy? (Zacks)
Mar-02-26 09:00AM	Is Trending Stock Coupang, Inc. (CPNG) a Buy Now? (Zacks)
Mar-01-26 06:43PM	Analyst Report: Coupang, Inc. (Morningstar Research)
09:58AM	Coupang (CPNG) Records $8.8B Q4 Revenue, $26M Loss Amid Data Breach Backlash (Insider Monkey)
Feb-27-26 09:14PM	Coupang Q4 Earnings Call Highlights (MarketBeat)
12:21PM	Loading…
12:21PM	Coupang Q4 Earnings Miss Estimates, Revenues Increase Y/Y, Stock Down (Zacks)
12:08AM	Coupang Inc (CPNG) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-26-26 08:00PM	Coupang (CPNG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:00PM	Coupang, Inc. (CPNG) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Coupang (NYSE:CPNG) Misses Q4 CY2025 Revenue Estimates (StockStory)
04:13PM	Coupang swings to loss as data breach dents Q4; sees muted near-term growth (Reuters)
04:13PM	Coupang reports Q4 revenue of $8.8 billion, missing analyst expectations (Reuters)
04:05PM	Coupang Announces Results for Fourth Quarter 2025 (Business Wire)
Feb-25-26 10:05PM	South Korea watchdog fines Coupang $1.6 million for pressuring suppliers, delaying payments (Reuters)
06:05PM	Coupang braces for increased competition amid fallout from South Korea data breach (Reuters)
06:18AM	Is Coupang (CPNG) One of the Best High Volume Stocks to Invest In Now? (Insider Monkey)
Feb-24-26 10:12PM	Coupang (CPNG) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
09:53AM	Coupang Set to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-23-26 10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
Feb-19-26 05:50PM	Coupang, Inc. (CPNG) Rises As Market Takes a Dip: Key Facts (Zacks)
10:00AM	Loading…
10:00AM	Earnings Preview: Coupang, Inc. (CPNG) Q4 Earnings Expected to Decline (Zacks)
09:30AM	Travelzoo (TZOO) Reports Break-Even Earnings for Q4 (Zacks)
Feb-17-26 06:00PM	Coupang, Inc. (CPNG) Outperforms Broader Market: What You Need to Know (Zacks)
06:30AM	Pennsylvania Small Businesses Expand into Global Markets With Assist from Coupang (Business Wire)
Feb-16-26 09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-14-26 01:19AM	Coupang (CPNG) Maintained at Buy With $24 PT (Insider Monkey)
Feb-13-26 04:52PM	Analyst Report: Coupang, Inc. (Morningstar Research)
09:30AM	Wall Street Analysts Think Coupang (CPNG) Is a Good Investment: Is It? (Zacks)
Feb-12-26 04:05PM	Coupang to Announce Fourth Quarter 2025 Results on February 26, 2026 (Business Wire)
02:24PM	SoftBank Vision Fund Posts $2.4 Billion Quarterly Gain (GuruFocus.com)
11:56AM	More US investors sue South Korean government over handling of Coupang data breach (TechCrunch)
02:40AM	SoftBank Swings to Profit on Valuation Boost From OpenAI Bet (Bloomberg)
Feb-11-26 08:57PM	More investors join legal challenge against South Korea over Coupang data leak handling (Reuters)
09:45AM	Abrams Capital, Durable Capital Partners, and Foxhaven Join Greenoaks and Altimeter in Legal Effort to End Korea's Discrimination Against U.S. Companies and Uphold U.S.-Korea Trade Commitments (Business Wire)
Feb-10-26 05:50PM	Coupang, Inc. (CPNG) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
06:41AM	Bernstein Initiates Coverage of Coupang (CPNG) With an Underperform Rating (Insider Monkey)
06:41AM	South Korea Cites Key Failures in Coupang Data Breach (GuruFocus.com)
12:16AM	South Korea blames Coupang data breach on management failure, not sophisticated attack (Reuters)
Feb-09-26 12:05PM	Bernstein Initiates Coupang (CPNG) Coverage with Underperform Rating, $17 PT (Insider Monkey)
Feb-08-26 11:03PM	2 Reasons to Like CPNG (and 1 Not So Much) (StockStory)
Feb-05-26 11:59PM	BYDs $60 Billion Wipeout Points to Deeper Turmoil for China EVs (Bloomberg) -13.68% +5.54%
10:41AM	Coupang, Inc. (CPNG)'s Growth Engine Remains Intact Despite Temporary Uncertainty (Insider Monkey)
10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
03:58AM	Coupang confirms more data leaks which South Korean aide says has 'shaken' US ties (Reuters)
Feb-03-26 11:33PM	2 of Wall Street's Favorite Stocks on Our Watchlist and 1 Facing Headwinds (StockStory)
05:50PM	Coupang, Inc. (CPNG) Declines More Than Market: Some Information for Investors (Zacks)
Feb-02-26 07:47PM	Coupang, Inc. (CPNG): A Bull Case Theory (Insider Monkey)
09:00AM	Coupang, Inc. (CPNG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
01:30AM	The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh (Barrons.com)
Jan-31-26 03:51PM	Coupang, Inc. (CPNG) Shares in Focus Amid Mixed Signals (Insider Monkey)
Jan-30-26 01:58PM	The Nominee to Lead the Fed Must First Fire Corporate America (Barrons.com)
Jan-28-26 06:26PM	Stocks to Watch Wednesday Recap: Amazon, Nvidia, Deutsche Bank (The Wall Street Journal)
04:57PM	Tiffany Gonzalez from Bombyll to Speak at TechCon Southwest 2026 (TMX Newsfile)
10:50AM	Stocks to Watch Wednesday: Amazon, Nvidia, Deutsche Bank (The Wall Street Journal)
10:46AM	Trump Warns South Korea on Trade Deal as 25% Tariffs Loom (GuruFocus.com)
09:40AM	Stocks to Watch Wednesday: Amazon, Nvidia, Alibaba (The Wall Street Journal)
09:30AM	Coupang (CPNG) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Jan-27-26 07:05PM	U.S. Tries to Protect Tech Firms From South Korean Pressure (The Wall Street Journal)
06:53PM	U.S. Warns Korea Against Targeting American Tech Firms Amid Trade Escalation (The Wall Street Journal)
11:40AM	Why Coupang (CPNG) Stock Is Trading Up Today (StockStory)
08:38AM	Nomura Slashes Coupang (CPNG) 2026 EPS Forecast Following $900M Fine and Regulatory Pressure (Insider Monkey)
Jan-26-26 05:50PM	Coupang, Inc. (CPNG) Stock Sinks As Market Gains: What You Should Know (Zacks)
10:05AM	The Ultimate Growth Stock to Buy With $1,000 Right Now (Motley Fool)
Jan-23-26 12:43PM	Brad Gerstner Takes On South Korea Government Over Coupang Investment: 'America First Means A Level Playing Field' (Benzinga)
06:07AM	Stocks to Watch Friday: Intel, Capital One, CSX (The Wall Street Journal)
05:19AM	Coupang, Inc. (CPNG) Upgraded to Buy: Is the Worst of the Data Leak Over? (Insider Monkey)
04:46AM	US investors seek trade action over South Koreas handling of Coupang report (Retail Insight Network)
Jan-22-26 06:30AM	Greenoaks Takes Legal Action to Stop Korea's Discrimination Against Coupang and Other U.S. Companies (Business Wire)
06:10AM	Coupang investors seek US probe over South Korea's handling of data leak (Reuters)
Jan-21-26 06:00PM	Coupang, Inc. (CPNG) Stock Sinks As Market Gains: Here's Why (Zacks)
03:40PM	CPNG Stockholders Who Lost Money Investing in Coupang, Inc. Should Contact Robbins LLP for Information About Their Rights (PR Newswire)
09:00AM	Coupang, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CPNG (PR Newswire)
Jan-16-26 01:01PM	Coupang Upgrade Signals Worst May Be Over, Says Deutsche Bank (GuruFocus.com)
Jan-15-26 05:50PM	Coupang, Inc. (CPNG) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
06:38AM	Data Breach Hurts Coupang, Inc. (CPNG), But Analyst Keeps Overweight Rating (Insider Monkey)
Jan-12-26 09:30AM	Wall Street Analysts See Coupang (CPNG) as a Buy: Should You Invest? (Zacks)
Jan-09-26 05:50PM	Coupang, Inc. (CPNG) Rises Higher Than Market: Key Facts (Zacks)
09:00AM	Here is What to Know Beyond Why Coupang, Inc. (CPNG) is a Trending Stock (Zacks)
Jan-08-26 01:32PM	Coupang, Inc. (CPNG) Class Period Expanded in Pending Investor Securities Lawsuit - Hagens Berman (PR Newswire)
11:59AM	2 E-Commerce Stocks With More Growth Than Amazon (24/7 Wall St.)
Jan-07-26 11:33AM	2 Hypergrowth Tech Stocks to Buy in 2026 (Motley Fool)
Jan-06-26 06:00PM	Coupang, Inc. (CPNG) Laps the Stock Market: Here's Why (Zacks)
Jan-02-26 09:00AM	A $1 Billion Catalyst Just Hit Coupang. How Should You Play CPNG Stock Here? (Barchart)
09:00AM	Investors in Coupang, Inc. Should Contact Levi & Korsinsky Before February 17, 2026 to Discuss Your Rights - CPNG (PR Newswire)
Dec-31-25 11:38PM	3 Large-Cap Stocks to Research Further (StockStory)
05:50PM	Coupang, Inc. (CPNG) Declines More Than Market: Some Information for Investors (Zacks)
05:07PM	South Korean Stocks Had a Breakout 2025. Can It Continue? (Barrons.com)
10:20AM	2 Top Stocks That Could Soar in 2026 (Motley Fool)
Dec-29-25 04:46PM	Stocks to Watch Monday Recap: Lululemon, Newmont, DigitalBridge (The Wall Street Journal)

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MEHTA NEIL	Director	Mar 12 '26	Buy	18.68	3,000,000	56,036,100	52,978,114	Mar 13 09:04 PM
MEHTA NEIL	Director	Mar 13 '26	Buy	18.40	2,332,863	42,923,279	55,310,977	Mar 13 09:04 PM
MEHTA NEIL	Director	Mar 11 '26	Buy	18.64	2,017,241	37,603,591	49,978,114	Mar 13 09:04 PM
Lee Jonathan D.	Chief Accounting Officer	Jan 02 '26	Sale	23.62	2,679	63,278	122,096	Jan 02 04:51 PM
Jonathan Lee	affiliate	Jan 02 '26	Proposed Sale	23.62	2,679	63,278		Jan 02 04:07 PM
Pranam Kolari	Former Officer	Nov 17 '25	Proposed Sale	28.20	27,388	772,209		Nov 17 04:19 PM
Anand Gaurav	Chief Financial Officer	Nov 10 '25	Sale	29.02	75,350	2,186,619	1,941,590	Nov 12 04:34 PM
GAURAV ANAND	Officer	Nov 10 '25	Proposed Sale	28.88	75,350	2,176,108		Nov 10 04:34 PM
Kolari Pranam	VP, Search and Recommendations	Nov 03 '25	Sale	31.98	11,653	372,608	147,023	Nov 05 04:24 PM
Pranam Kolari	Officer	Nov 03 '25	Proposed Sale	31.98	11,653	372,608		Nov 03 04:15 PM
Franceschi Pedro	Director	Sep 11 '25	Sale	32.05	21,428	686,767	0	Sep 12 04:21 PM
Rogers Harold	See Remarks	Sep 11 '25	Sale	32.06	64,755	2,075,793	449,569	Sep 12 04:20 PM
Pedro Franceschi	Director	Sep 11 '25	Proposed Sale	32.12	21,428	688,267		Sep 11 05:17 PM
Harold Rogers	Affiliate	Sep 11 '25	Proposed Sale	32.06	64,755	2,075,795		Sep 11 04:16 PM
Sun Benjamin	Director	Sep 09 '25	Sale	31.88	815,797	26,007,626	503,624	Sep 10 04:49 PM
Benjamin Sun	Affiliate	Sep 09 '25	Proposed Sale	31.88	815,797	26,007,404		Sep 09 04:47 PM
Han Seung Kang	affiliate	Aug 28 '25	Proposed Sale	28.24	25,000	706,000		Aug 28 04:07 PM
SVF Investments (UK) Ltd	10% Owner	Aug 20 '25	Sale	28.00	20,000,000	560,000,000	289,542,259	Aug 22 09:00 PM
SVF Investments (UK) Ltd	Shareholder	Aug 20 '25	Proposed Sale	28.84	20,000,000	576,800,000		Aug 20 09:00 PM
Anand Gaurav	Chief Financial Officer	Aug 11 '25	Sale	27.79	75,350	2,093,803	2,016,940	Aug 12 04:34 PM
GAURAV ANAND	Officer	Aug 11 '25	Proposed Sale	27.83	75,350	2,096,990		Aug 11 04:22 PM
Kolari Pranam	VP, Search and Recommendations	Aug 04 '25	Sale	29.14	11,653	339,568	158,676	Aug 04 04:41 PM
Pranam Kolari	affiliate	Aug 04 '25	Proposed Sale	29.14	11,653	339,568		Aug 04 04:24 PM
SVF Investments (UK) Ltd	10% Owner	Jun 13 '25	Sale	28.25	10,000,000	282,500,000	309,542,259	Jun 17 09:00 PM
SVF Investments (UK) Ltd	Shareholder	Jun 13 '25	Proposed Sale	28.31	10,000,000	283,100,000		Jun 13 09:00 PM
Anand Gaurav	Chief Financial Officer	May 29 '25	Sale	28.11	175,000	4,919,635	2,092,290	Jun 02 04:21 PM
Sun Benjamin	Director	May 28 '25	Sale	28.36	200,000	5,671,560	1,319,421	May 30 04:39 PM
Gaurav Anand	affiliate	May 29 '25	Proposed Sale	28.11	175,000	4,919,627		May 29 06:12 PM
Benjamin Sun	Affiliate	May 28 '25	Proposed Sale	28.33	200,000	5,665,552		May 28 04:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 14 '25	Buy	26.78	750,000	20,082,300	54,481,161	May 16 07:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 15 '25	Buy	26.86	650,000	17,458,610	55,131,161	May 16 07:30 PM
Anand Gaurav	Chief Financial Officer	May 12 '25	Sale	26.10	75,350	1,966,921	2,267,290	May 14 04:21 PM
SVF Investments (UK) Ltd	10% Owner	May 08 '25	Sale	25.75	30,000,000	772,500,000	319,542,259	May 12 09:00 PM
GAURAV ANAND	Officer	May 12 '25	Proposed Sale	26.00	75,350	1,959,100		May 12 04:23 PM
Sun Benjamin	Director	May 08 '25	Sale	26.03	200,000	5,206,120	1,519,421	May 12 04:15 PM
Kang Hanseung	Rep Director, Business Mngmt	May 08 '25	Sale	26.17	69,931	1,830,248	599,841	May 12 04:14 PM
Lee Jonathan D.	Chief Accounting Officer	May 08 '25	Sale	26.17	8,105	212,126	124,775	May 12 04:12 PM
Kolari Pranam	VP, Search and Recommendations	May 08 '25	Sale	26.17	6,777	177,385	170,329	May 12 04:10 PM
SVF Investments (UK) Ltd	Shareholder	May 08 '25	Proposed Sale	26.60	30,000,000	798,000,000		May 08 09:00 PM
Pranam Kolari	affiliate	May 08 '25	Proposed Sale	26.17	6,777	177,385		May 08 04:35 PM
Benjamin Sun	Affiliate	May 08 '25	Proposed Sale	26.00	200,000	5,199,322		May 08 04:29 PM
Han Seung Kang	affiliate	May 08 '25	Proposed Sale	26.17	69,931	1,830,247		May 08 04:29 PM
Jonathan Lee	affiliate	May 08 '25	Proposed Sale	26.17	8,105	212,127		May 08 04:22 PM
Kolari Pranam	VP, Search and Recommendations	May 02 '25	Sale	23.85	9,347	222,926	177,106	May 02 09:16 PM
Pranam Kolari	affiliate	May 02 '25	Proposed Sale	23.47	9,347	219,374		May 02 08:34 PM

Open in Screener

ROIV

Roivant Sciences Ltd

Apr 10 • 04:00PM ET

28.21

-0.27 -0.95 %

Healthcare • Biotechnology • United Kingdom • NASD

ROIV Roivant Sciences Ltd daily Stock Chart

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB VBK VXF XMMO IBB MDY XBI SPMD

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	31.76%	Shs Outstand	709.69M	Perf Week	-0.42%
Market Cap	20.19B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-10.56%	Shs Float	488.39M	Perf Month	-4.63%
Enterprise Value	16.47B	PEG	-	EPS next Q	-0.29	Inst Own	68.32%	Short Float	5.10%	Perf Quarter	29.52%
Income	-809.24M	P/S	1516.90	EPS this Y	-366.11%	Inst Trans	2.15%	Short Ratio	4.00	Perf Half Y	75.98%
Sales	13.31M	P/B	4.69	EPS next Y	-5.54%	ROA	-14.69%	Short Interest	24.88M	Perf YTD	30.00%
Book/sh	6.02	P/C	4.45	EPS next 5Y	-	ROE	-17.11%	52W High	30.33 -6.99%	Perf Year	192.33%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-18.53%	52W Low	9.24 205.30%	Perf 3Y	282.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	60.46%	Volatility	2.47% 3.32%	Perf 5Y	186.98%
Dividend TTM	-	EV/Sales	1237.51	EPS Y/Y TTM	-751.06%	Oper. Margin	-9130.53%	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.66	Sales Y/Y TTM	-86.36%	Profit Margin	-6079.94%	RSI (14)	54.56	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	30.66	EPS Q/Q	-262.80%	SMA20	1.71%	Beta	1.22	Target Price	34.82
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.83%	SMA50	3.82%	Rel Volume	0.50	Prev Close	28.48
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	46.00%	Avg Volume	6.22M	Price	28.21
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.41% -60.65%	Trades		Volume	3,119,664	Change	-0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Outperform	$35
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-02-26 05:00AM	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
05:00AM	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) (GlobeNewswire)
Mar-28-26 03:00PM	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis (GlobeNewswire)
Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily) +6.00%
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	Loading…
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
06:38AM	Loading…
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
02:00AM	Loading…
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Humes Jennifer	Chief Accounting Officer	Apr 08 '26	Sale	28.37	13,538	384,073	84,191	Apr 10 06:00 PM
JENNIFER HUMES	Officer	Apr 08 '26	Proposed Sale	28.37	13,538	384,035		Apr 08 04:07 PM
Fitzgerald Meghan	Director	Mar 26 '26	Option Exercise	8.80	70,000	616,000	112,963	Mar 30 09:01 PM
Fitzgerald Meghan	Director	Mar 26 '26	Sale	27.45	70,000	1,921,500	42,963	Mar 30 09:01 PM
MEGHAN FITZGERALD	Director	Mar 26 '26	Proposed Sale	27.45	70,000	1,921,458		Mar 26 04:14 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Mar 19 06:36 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Sale	28.24	200,000	5,648,000	1,647,546	Mar 19 06:36 PM
Epperly Melissa B,	Director	Mar 16 '26	Sale	28.68	41,861	1,200,573	15,804	Mar 18 06:23 PM
Venker Eric	Officer	Mar 17 '26	Proposed Sale	28.24	200,000	5,648,836		Mar 17 04:17 PM
MELISSA B EPPERLY	Director	Mar 16 '26	Proposed Sale	28.68	41,861	1,200,498		Mar 16 04:04 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM
Sukhatme Mayukh	Officer	Feb 09 '26	Proposed Sale	26.47	339,441	8,985,276		Feb 09 04:13 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM

CPNG

Coupang Inc

ROIV

Roivant Sciences Ltd

Upgrade your Finviz experience